Trial Profile
Profile of leukocyte populations in patients with psoriasis who are responders and nonresponders to treatment with efaluzimab (anti-CD11a): study systemic and cutaneous.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2012
Price :
$35
*
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms REPSORA
- 25 Aug 2011 New trial record